Phase 1 trial in Sweden to test IRL757 for neurological apathy
Irlab Therapeutics is preparing to start a Phase 1 clinical trial of IRL757, its oral tablet candidate to ease apathy in Parkinson’s disease and other neurological conditions. The trial, which follows its approval by the Swedish Medical Products Agency, is fully financed by a 20 million SEK (about…